Myogenic Cell Expansion via Defined Growth Factor Medium

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods fail to reproducibly generate sufficient amounts of pure, differentiated human skeletal muscle cells from pluripotent stem cells, hindering the development of therapies for skeletal muscle disorders due to low yields and variable viability of myogenic cells after differentiation.

Innovation Solution

Established culturing conditions allow for the expansion of myogenic cells up to 7×10^6 fold, enabling the generation of homogeneous, terminally differentiated myotubes and myofibers, which can be used for in vitro testing and drug screening, using a synthetic culture medium with FGF2 and specific differentiation protocols.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If small molecules activating WNT pathway are used to drive stem cell differentiation into myogenic lineage, then differentiation is achieved, but cell recovery after purification is low and viability is variable

Engineering Contradiction:

Improvedifferentiation potentialVSAvoidcell recovery

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the chemical parameters of the culture medium by replacing small molecule WNT pathway activators with defined concentrations of growth factors (FGF2 at 100 ng/ml, IGF-1 at 100 ng/ml, HGF at 100 ng/ml) and serum-free conditions. This parameter change maintains differentiation potential while dramatically improving cell recovery from 250,000 to over 7 million cells, achieving both reliability and productivity

Inventive Principle:

Principle #35Parameter changes

2Reliability

If transgene overexpression of MyoD or Pax7 is used to drive myogenic differentiation, then differentiation markers are achieved, but the method is difficult to implement and yields are low

Engineering Contradiction:

Improvemyogenic differentiationVSAvoiddifferentiation method complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts and eliminates the need for complex transgene overexpression systems by using a simplified culture medium approach. Instead of introducing external genes through viral vectors or transfection, the method uses extracted and optimized growth factor combinations that naturally drive myogenic differentiation, making the process easier to manufacture while maintaining reliable differentiation

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent substitutes the mechanical/genetic manipulation system (transgene overexpression) with a biochemical system (growth factor-mediated signaling). This replacement eliminates the complexity of genetic engineering steps while achieving the same myogenic differentiation outcome through natural growth factor pathways

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Quantity of substance

If conventional culturing methods are used for pluripotent stem cells, then cell maintenance is achieved, but sufficient amounts of pure differentiated skeletal muscle cells cannot be generated

Engineering Contradiction:

Improveamount of differentiated cellsVSAvoidpurity of skeletal muscle cells

Core Design Contradiction:

Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent applies preliminary action by optimizing the culture medium composition before differentiation occurs. The serum-free medium with specific growth factors (FGF2, IGF-1, HGF) is prepared in advance to guide pluripotent stem cells through controlled differentiation into pure myogenic cells, ensuring both high quantity and high purity without requiring post-differentiation purification steps

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables large-scale generation of myogenic cells with maintained myogenic potential, overcoming the limitations of low yields and variable viability, facilitating quantitative in vitro testing and drug discovery for muscle diseases.

Implementation Method 1

an expanded cell culture obtained by a method of the invention constitutes a novel class of myogenic cells, which are homogeneous and can be held in culture for a prolonged period of time. These cells are highly expandable when cultured under the appropriate conditions

Methodology Applied

Scientific EffectFGF2 signaling:

Data Source

PatentUS20220380730A1Method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium

Publication Date: 2022.12.01 ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC

AI summary

The invention is in the field of cell culturing. More specifically, it is in the field of generating and expanding myogenic cells from induced pluripotent stem (iPS) cells. The invention relates inter alia to cells generated and expanded via such a method, a growth medium specifically suited for the purpose of expanding isolated myogenic cells, and methods for screening compounds on cell structures such as myotubes and myofibers.